Contrasting PTH Response of Denosumab Use in Dialysis Patients: A Report of 2 Cases

A common complication of end-stage renal disease (ESRD) is mineral and bone disorder. Yet, many anti-osteoporotic drugs are contraindicated in ESRD patients. Denosumab, a monoclonal antibody, does not require renal dose adjustment. However, its use is uncertain due to a lack of safety and efficacy o...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Soo Min, Anam, Smitha, Pringle, Tara, Lahren, Paul, Infante, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355881/
https://www.ncbi.nlm.nih.gov/pubmed/32244607
http://dx.doi.org/10.3390/pharmacy8020059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355881/
https://www.ncbi.nlm.nih.gov/pubmed/32244607
http://dx.doi.org/10.3390/pharmacy8020059

Ejemplares similares